The favourable safety profile of vedolizumab in patients with inflammatory bowel disease (IBD) persists even in real-world clinical practice, according to the first 4 years of post-marketing safety data reported at AIBD 2018.
The incidence of Clostridium difficile (C. difficile) infection among patients with ulcerative colitis (UC) who are receiving treatment with tofacitinib is low and particularly so when compared with C. difficile infection incidence in patients receiving other UC therapies, according to a poster presented at AIBD 2018.
Older patients receiving treatment for ulcerative colitis (UC) were more likely to experience adverse events (AEs) compared with their younger counterparts, according to a study presented at AIBD 2018.
Patients with obesity have an elevated risk of intra- and postoperative complications following surgical treatment for inflammatory bowel disease (IBD), according to a presentation at the recent Advances in Inflammatory Bowel Disease meeting (AIBD 2018).
Ferric carboxymaltose (FCM) remains the most effective intravenous (IV) iron formulation as monotherapy followed by iron sucrose/saccharate (IS) and presented a better safety profile with fewer adverse events (AEs) in patients with inflammatory bowel disease (IBD) with iron deficiency anaemia (IDA), according to an updated meta-analysis presented at AIBD 2018.
The α4β7 integrin antibody vedolizumab continues to show efficacy and safety in patients with inflammatory bowel disease (IBD) in an era beyond tumour necrosis factor (TNF) inhibitors, according to a presentation at the annual Advances in Inflammatory Bowel Diseases (AIBD) 2018 meeting.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.